NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
Clinical Trials
20 trialsNCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT01279291 2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT04814875 2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Phase 1/2 Terminated
NCT01485874 2022-02-15
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Hoosier Cancer Research Network
Phase 1 Terminated
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT01170650 2021-09-30
PROCEED
Endocyte
Phase 3 Terminated
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT01227941 2016-10-19
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Tesaro, Inc.
Phase 1 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00312650 2015-01-12
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Women and Infants Hospital of Rhode Island
Phase 2 Terminated
NCT01202890 2014-01-08
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00350948 2013-11-27
ASSIST-5
Telik
Phase 3 Terminated
NCT01016054 2013-02-27
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Astellas Pharma Inc
Phase 1 Terminated
NCT00653328 2012-05-23
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00653952 2010-04-27
CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00179725 2006-04-12
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Celgene
Phase 1/2 Terminated